Tetra Bio-Pharma news

• Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag.
• Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption.
• This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 2022.

OTTAWA, ON, May 10, 2022&n

• Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users.
• The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD.

OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader

OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million. The Offering was co